Galmed Pharma (GLMD) Tops Q3 EPS by 19c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of $0.05, $0.19 better than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• SanDisk stock target lifted by Citi on continued demand strength
• Darden Restaurants (DRI) Tops Q4 EPS by 3c, Misses on Revenue; Offers FY27 Guidance
• SYNNEX Corp. (SNX) Tops Q2 EPS by 74c, Beats on Revenue; Offers Q3 Guidance